## **Appendix 1 Supplementary methods**

Post-hoc power analyses were conducted for the primary study endpoint—changes in estimated glomerular filtration rate (eGFR) over the study duration—in the overall population and different study groups. These analyses focused on the withineffect test for mean differences among measurements using repeated measures ANOVA and the differences between the 12-month and 0-month time points assessed using paired t-tests. Power calculations were performed using the R package 'WebPower' (1).

## References

1. Zhang Z, Yuan KH. Practical Statistical Power Analysis Using Webpower and R (Eds). Granger, IN: ISDSA Press, 2018.

Group -	Repeated measures ANOVA			Paired t-test	
	F	Nonsphericity correction coefficient	Power	Effect size	Power
Overall (n=43)	5.332	0.626	1.000	0.602	0.971
According to baseline eGFR (mL/min/1.73 m <sup>2</sup> )					
≥90 (n=7)	0.782	0.560	0.192	1.130	0.703
60–89 (n=8)	2.173	0.433	0.905	0.863	0.556
30–59 (n=13)	4.128	0.421	1.000	0.902	0.847
15–29 (n=5)	0.128	1.000	0.053	-0.105	0.054
0–14 (n=10)	0.533	0.213	0.106	0.241	0.105
According to the final daily tolvaptan dose (mg)					
15 (n=14)	0.533	0.412	0.173	0.220	0.119
>15–30 (n=22)	2.562	0.604	1.000	0.757	0.923
>30-60 (n=7)	4.655	0.358	1.000	1.218	0.766

Table S1 Post-hoc power analysis results for changes in eGFR over the study duration

eGFR, estimated glomerular filtration rate.